1830 / 1851
Toxicity of concurrent SRT and
immune checkpoint inhibition
Anti-CTLA-4 (ipilimumab)
Concurrent cranial SRT with ipilimumab
is safe.
Limited data on the use ipilimumab
concurrent with extra-cranial SRT.
Kroeze S et al. Cancer Treatment Reviews 53 (2017) 25–37